Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population

Journal of Hepatology

Volumn 56, Issue 5, 2012, Pages 1089-1096

  Cucchetti, Alessandro ^a   Trevisani, Franco ^a   Cescon, Matteo ^a   Ercolani, Giorgio ^a   Farinati, Fabio ^b   Poggio, Paolo Del ^c   Rapaccini, Gianludovico ^d   Nolfo, Maria Anna Di ^e   Benvegnù, Luisa ^b   Zoli, Marco ^a   Borzio, Franco ^f   Giannini, Edoardo Giovanni ^g   Caturelli, Eugenio ^h   Chiaramonte, Maria ⁱ   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e BOLOGNINI HOSPITAL   (Italy)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

ⁱ SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Cirrhosis; Cost effectiveness; Diagnosis; Hepatocellular carcinoma; Markov model; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEALTH CARE COST; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RADIOFREQUENCY ABLATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84859702722     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.11.022     Document Type: Article

References (30)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
2. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-335. (Pubitemid 30078596)
3. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, Zoli M, et al. Semi-annual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-744. (Pubitemid 34245906)
4. Chalasani N, Horlander Sr JC, Said A, Hoen H, Kopecky KK, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999;94:2988-2993. (Pubitemid 29482770)
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:4210-4230.
6. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
7. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semi-annual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297.
8. Mark DB. Economic analysis: methods and endpoints. In: Califf RM, Mark DB, Wagner G, editors. Acute coronary care. St. Louis: Mosby-YearBook; 1995. p. 167-182.
9. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-888. (Pubitemid 13211834)
10. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231. (Pubitemid 41772537)
11. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127: S35-S50. (Pubitemid 39423368)
12. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801. (Pubitemid 23174709)
13. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008;28:582-592. (Pubitemid 351989999)
14. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 1996;276:1172-1177. (Pubitemid 26329746)
16. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting costeffectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996;276:1339-1341.
17. Ruggeri M, Cicchetti A, Gasbarrini A. Health Policy 2010:27.
18. Tampellini M, Bitossi R, Brizzi MP, et al. Pharmacoeconomica comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal carcinoma: a cost-minimization study. Tumori 2004;90:44-49. (Pubitemid 38541726)
19. Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg 2009;198:396-406.
20. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010;51:165-173.
21. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-1118.
22. Chalasani N, Horlander Sr JC, Said A, Hoen H, Kopecky KK, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999;94:2988-2993. (Pubitemid 29482770)
23. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422-434. (Pubitemid 26392861)
24. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-1424.
25. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008;98:1166-1175. (Pubitemid 351481685)
26. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-690. (Pubitemid 36348544)
27. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
28. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-527. (Pubitemid 36258772)
29. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-574.
30. Poustchi H, Farrell G, Strasser S, et al. Feasibility of conducting a randomised control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 2011. doi:10.1002/hep. 24581.